ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China

Posted: October 13, 2022 at 2:26 am

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

Go here to read the rest:
ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China

Related Posts